Home > List All Publishers > La Merie Publishing

La Merie Publishing

La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence by Publishing, Consultancy and its Biotech Portal PipelineReview.com. The information is retrieved from La Merie’s in house R&D database, news portal and direct as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.

La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies.
The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as a la carte or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are elaborated by independent analysts of La Merie Business Intelligence. Brief Reports on Target Pipelines include assessment of the scientific as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.

List of reports from La Merie Publishing

Competitor Analysis: MTP Inhibitors 9/14/2008 \| published by: La Merie Publishing ... compilation of current active projects in research and development of novel MTP inhibitors. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, ... \| more... Search inside this report	$70.00
Competitor Analysis: CD30 Antibodies 1/26/2009 \| published by: La Merie Publishing ... compilation of current active projects in research and development of anti-CD22 antibodies. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product ... \| more... Search inside this report	$70.00
Competitor Analysis: CEA Antibodies 4/7/2009 \| published by: La Merie Publishing ... includes a compilation of current active projects in research and development of epithelial cell adhesion molecule (EpCAM) targeting antibodies and antibody-based constructs. In addition, the report lists company-specific R&D pipelines of EpCAM Antagonists. Competitor projects ... \| more... Search inside this report	$70.00
Competitor Analysis: Immunotherapy of S. aureus Infections 7/20/2008 \| published by: La Merie Publishing ... of current active projects in research and development of novel antibodies and vaccines against S. aureus. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class ... \| more... Search inside this report	$70.00
Competitor Analysis: CETP Inhibitors 9/14/2008 \| published by: La Merie Publishing ... a compilation of current active projects in research and development of novel CETP inhibitors. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ... \| more... Search inside this report	$70.00
Competitor Analysis: MEK Inhibitors 10/23/2008 \| published by: La Merie Publishing ... the companies active in the field of MEK inhibitors are Big Pharma and kinase inhibitor specialist biotech companies. The report includes a compilation of current active projects in research and development of MEK Inhibitors. Competitor ... \| more... Search inside this report	$105.00
Competitor Analysis: CD22 Antibodies 1/26/2009 \| published by: La Merie Publishing ... 2009. The report includes a compilation of current active projects in research and development of anti-CD22 antibodies. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, ... \| more... Search inside this report	$105.00
Competitor Analysis: CD19 Antagonists 1/26/2009 \| published by: La Merie Publishing ... 2009. The report includes a compilation of current active projects in research and development of anti-CD19 antibodies. Competitor projects are listed in a tabular format providing information on: Drug Codes, Target / Mechanism of Action, ... \| more... Search inside this report	$105.00
Competitor Analysis: Malaria Vaccines 5/1/2010 \| published by: La Merie Publishing ... Malaria as of May 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will ... \| more... Search inside this report	$129.00
Competitor Analysis: Dengue Virus Vaccines 3/1/2010 \| published by: La Merie Publishing ... 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail ... \| more... Search inside this report	$134.00
Competitor Analysis: Notch Pathway Inhibitors 2/1/2010 \| published by: La Merie Publishing ... the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online ... \| more... Search inside this report	$136.00
Competitor Analysis: BlyS, BAFF & APRIL Antagonists 2/1/2010 \| published by: La Merie Publishing ... a proliferation-inducing ligand (APRIL) as of February 2010. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access ... \| more... Search inside this report	$136.00
Competitor Analysis: Alzheimer’s Disease Antibodies 7/6/2008 \| published by: La Merie Publishing ... companies active in the field of new antibodies for passive immunotherapy of Alzheimer’s disease Wyeth, Elan, Pfizer, Roche and many others. The report includes a compilation of current active projects in research and development of ... \| more... Search inside this report	$140.00
Competitor Analysis: Sodium-dependent glucose (co-) transporter (SGLT) Inhibitors 11/4/2008 \| published by: La Merie Publishing ... (SGLT are specifically expressed in the intestines (SGLT-1) and kidneys (SGLT-1). Inhibitors of SGLT-1 suppress absorption of glucose from the gut, while SGLT-2 inhibitors block the reabsorptoin of glucose from the renal filtrate. Thus, SGLT ... \| more... Search inside this report	$140.00
Competitor Analysis: Interleukin-6 (IL-6) and Receptor (IL-6R) Antagonists 2/2/2009 \| published by: La Merie Publishing ... Receptor (IL-6R) Antagonists as of February 2009. Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is ... \| more... Search inside this report	$140.00
Competitor Analysis: EpCAM Antagonists 4/1/2009 \| published by: La Merie Publishing ... 2009. Epithelial cell adhesion molecule (EpCAM; CD326) is a cell surface protein that is frequently expressed at high level on most solid tumor types, including prostate, breast, colon, gastric, ovarian, pancreatic and lung cancer. Overexpression ... \| more... Search inside this report	$140.00
Competitor Analysis: Hypoxia-Inducible Factor (HIF) 4/24/2009 \| published by: La Merie Publishing ... agonists to induce angiogenesis as of April 2009. Hypoxia-inducible factor 1 (HIF-1) is a key regulator of angiogenic and glucose metabolism processes utilised by tumour cells for survival and growth under hypoxic conditions. While HIF-1α ... \| more... Search inside this report	$140.00
Competitor Analysis: NGF Agonists & Antagonists 5/1/2009 \| published by: La Merie Publishing ... or Alzheimer’s disease and peripheral neuropathies as of May 2009. Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous ... \| more... Search inside this report	$140.00
R&D Pipeline News - Technology Edition: 1-Month Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Technology Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given ... \| more...	$140.00
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Therapeutic Area Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a ... \| more...	$140.00
Competitor Analysis: Interleukin-1 (IL-1) and IL-1 receptor (IL-1R) Antagonists 2/8/2009 \| published by: La Merie Publishing ... Interleukin-1 (IL-1) and Receptor (IL-1R) Antagonists as of February 2009. Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. ... \| more... Search inside this report	$140.00
Competitor Analysis: PARP Inhibitors 4/15/2009 \| published by: La Merie Publishing ... (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modification and cell signaling. Over-activation of PARP results in pathologic alteration of cellular ... \| more... Search inside this report	$140.00
Competitor Analysis: Proteasome Inhibitors 11/1/2009 \| published by: La Merie Publishing ... downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work ... \| more... Search inside this report	$150.00
Competitor Analysis: C5a-R Antagonists 10/1/2010 \| published by: La Merie Publishing ... receptor for the treatment of inflammatory diseases as of October 2010. The molecules used to antagonize the interaction of C5a with C5aR include antibodies, proteins, peptides, nucleic acid macromolecules such as aptamers, vaccines and small ... \| more... Search inside this report	$173.00
Competitor Analysis: Adenosine Receptor Agonists & Antagonists 5/4/2008 \| published by: La Merie Publishing ... clinical development of Adenosine Receptor Agonists & Antagonistsas of May 2008. The report includes a compilation of current active projects in research and development of agonists and antagonists of the adenosine receptor subtypes 1, 2A, ... \| more... Search inside this report	$175.00

< prev 1 2 3 4 5 6 next >